Next, the authors tested the combination of IL2-NHS with RT (5 × 4 Gy to a single pulmonary nodule) in patients with metastatic NSCLC and showed that this approach is not only safe, but can also lead to long-term survival. This evidence concerns the gene IL2 and non-small cell lung carcinoma.